2nd Quarter - Report

THE MCMANUS GROUP for EMD SERONO, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to commercial delinking of PBMs in H.R.6283 - DRUG Act, S.1542 - DRUG Act H.R.7085 - BIOSECURE Act Issues related to IVF treatments.

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALEX WHALEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 3430 (118th), H.R. 6283 (118th), H.R. 3290 (118th), H.R. 7085 (118th), S. 1542 (118th), H.R. 5378 (118th)

Medicare/Medicaid MMM

Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act, S. 2973 - The Modernizing and Ensuring PBM Accountability (MEPA) Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALEX WHALEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5378 (118th), S. 3430 (118th), H.R. 8261 (118th), S. 1967 (118th), S. 2973 (118th), H.R. 2880 (118th)

Taxation/Internal Revenue Code TAX

Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023.

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALEX WHALEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2673 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.